Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

NCT02727699 is registered in ClinicalTrials.gov with Actinogen Medical as lead sponsor.

NCT NCT02727699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02727699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)
Lead sponsor
Actinogen Medical
Phase
Phase 2
Overall status
Completed
Start date
March 23, 2017
Completion date
March 15, 2019
Enrollment
185 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, alzheimer type